13 Schizophrenia Clinical Trials in Little Rock, AR (2026)

Q: How do I join a clinical trial in Little Rock?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Little Rock research site will contact you.

Recruiting Schizophrenia Studies in Little Rock

NCT05184335Recruiting

Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia

This study is to evaluate the effect and safety of Brilaroxazine in patients with acute schizophrenia compared to the placebo short and long-term. Brilaroxazine will be given at fixed doses of 15 mg o...

Little Rock, ARPHASE3690 participantsReviva Pharmaceuticals

View Study Details

NCT07114874Recruiting

NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia

This study will evaluate the long-term safety of NBI-1117568 in adults with schizophrenia....

Little Rock, ARPHASE3600 participantsNeurocrine Biosciences

View Study Details

NCT06894212Recruiting

A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia

This is a Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Determine the the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants with Schizophrenia...

Little Rock, ARPHASE3522 participantsOtsuka Pharmaceutical Development & Commercialization, Inc.

View Study Details

NCT07363577Recruiting

Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia

This is a Phase 3, randomized, double blind, placebo controlled, fixed dose, study designed to evaluate the efficacy, safety, tolerability, and of LB-102 versus placebo for the treatment of adult pati...

Little Rock, ARPHASE3456 participantsLB Pharmaceuticals Inc.

View Study Details

NCT07410507Recruiting

A Study of Brenipatide in Adult Participants With Schizophrenia

The purpose of this study is to assess the efficacy and safety of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC for treatment of schizophrenia. The trial is d...

Little Rock, ARPHASE2450 participantsEli Lilly and Company

View Study Details

NCT06229210Recruiting

Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder

This is a multicenter, global, 26-week, open-label study to assess the safety and tolerability of lumateperone in pediatric patients with schizophrenia, bipolar disorder or autism spectrum disorder....

Little Rock, ARPHASE3300 participantsIntra-Cellular Therapies, Inc.

View Study Details

NCT06963034Recruiting

NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults....

Little Rock, ARPHASE3284 participantsNeurocrine Biosciences

View Study Details

NCT05304767Recruiting

An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

This is a Phase 3, multicenter, 52-week, outpatient, open-label extension (OLE) study to evaluate the long-term safety and tolerability of adjunctive KarXT in subjects with schizophrenia with an inade...

Little Rock, ARPHASE3280 participantsKaruna Therapeutics

View Study Details

NCT07145918Recruiting

A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia

Schizophrenia is a common and severe psychiatric illness characterized by extreme disturbances of cognition and thought, affecting language, perception and sense of self. This study will assess advers...

Little Rock, ARPHASE2268 participantsAbbVie

View Study Details

NCT05303064Recruiting

Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder

To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapine...

Little Rock, ARPHASE3220 participantsAlkermes, Inc.

View Study Details

NCT07191483Recruiting

A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia

This is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) effects of 3 different dose regiments of KYN-5356 ...

Little Rock, ARPHASE2150 participantsKynexis B.V.

View Study Details

NCT05648591Recruiting

Safety and Tolerability of Open-Labeled Iloperidone in Adolescents

To evaluate the safety and tolerability of iloperidone in adolescent patients with schizophrenia or bipolar I disorder for up to 52 weeks of treatment....

Little Rock, ARPHASE4100 participantsVanda Pharmaceuticals

View Study Details

NCT07221877Recruiting

A Study to Evaluate the Effect of KarXT on Urological Safety

The purpose of this study is to characterize the effect of KarXT on voiding dynamics and urological safety in participants with DSM-5 schizophrenia....

Little Rock, ARPHASE460 participantsBristol-Myers Squibb

View Study Details

About Schizophrenia Clinical Trials in Little Rock

Schizophrenia is a chronic brain disorder affecting approximately 2.8 million US adults, characterized by hallucinations, delusions, disorganized thinking, and cognitive difficulties. While current treatments rely primarily on first- and second-generation antipsychotics (risperidone, olanzapine, clozapine), many patients experience incomplete symptom relief or significant side effects. Clinical trials are testing novel mechanisms including muscarinic receptor agonists (like KarXT/xanomeline-trospium), trace amine-associated receptor 1 (TAAR1) agonists, glutamate modulators, and long-acting injectable formulations. Treatment-resistant schizophrenia remains a major focus area, with trials seeking patients who have not adequately responded to standard antipsychotic therapy.

There are currently 13 schizophrenia clinical trials recruiting participants in Little Rock, AR. These studies are seeking a combined 4,380 participants. Research is being sponsored by Reviva Pharmaceuticals, Neurocrine Biosciences, Otsuka Pharmaceutical Development & Commercialization, Inc. and 9 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Schizophrenia Clinical Trials in Little Rock — FAQ

Are there schizophrenia clinical trials in Little Rock?

Yes, there are 13 schizophrenia clinical trials currently recruiting in Little Rock, AR. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Little Rock?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Little Rock research site will contact you about next steps.

Are clinical trials in Little Rock free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Little Rock studies also compensate for your time and travel.

What schizophrenia treatments are being tested?

The 13 active trials in Little Rock are testing new therapies including novel drugs, biologics, and treatment approaches for schizophrenia.

Data updated July 17, 2026 from ClinicalTrials.gov